FiercePharma

Teva Announces COPAXONE(R) Recognized as "Brand of the Year" by Pharmaceutical Executive Magazine

JERUSALEM--(BUSINESS WIRE)--May 8, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that COPAXONE® (glatiramer acetate injection), the #1 global therapy for relapsing multiple ...
FiercePharma

Teva Files Citizen Petition with the U.S. Food and Drug Administration (FDA) Regarding the Complexity of COPAXONE® (glatiramer acetate) Following the Agency's Guidance

Teva Files Citizen Petition with the U.S. Food and Drug Administration (FDA) Regarding the Complexity of COPAXONE® (glatiramer acetate) Following the Agency's Guidance Teva includes new gene ...
Business Wire

Teva’s COPAXONE® 40mg – Favorable Response from European Patent Office

COPAXONE ® (glatiramer acetate injection) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. The most common side effects of COPAXONE ® are redness, pain, swelling, ...
Medical Xpress

Research team discovers how Copaxone protects the heart muscle and improves its function after heart attack

In the late 1960s, three Weizmann Institute of Science researchers developed several protein-like molecules, called copolymers, that they believed would produce a disease similar to multiple sclerosis ...
FierceBiotech

Treatment with COPAXONE® in Multiple Sclerosis Demonstrated Remyelination and Neuroprotective Effects in a Preclinical Set

Additional Preclinical Data to be Presented at the Fifth Joint Triennial Congress of ECTRIMS and ACTRIMS Further Elucidate the Anti-inflammatory Mechanism of COPAXONE® JERUSALEM--(BUSINESS WIRE)-- ...
JD Supra

Invalidity Of Copaxone Patents Supported By Statements To FDA

In In re Copaxone Consolidated Cases, the Federal Circuit affirmed the district court decision finding four patents directed to a specific dosing regimen for using COPAXONE® 40 mg/ml to treat patients ...